融創公益基金會向中山大學捐贈3,500萬人幣
融創中國(01918.HK)公布,融創集團與中山大學簽署捐贈協議,融創公益基金會向中山大學捐贈3,500萬元人民幣(下同),並設立「中山大學融創公共衛生發展基金」,用於中山大學公共衛生人才培養、師資隊伍建設、學科建設、國際合作、學生獎助金等。融創中國未來將與中山大學就高校人才培養及見習就業方面建立長期合作關係,引導及支持學校就著科研創新及公共衛生領域的科研成果的發展,冀能助力衛生教育事業的開展與革新。
融創公益基金會自2018年成立以來,已累計捐贈超過21億元,聚焦教育扶智、鄉村振興與古建保護三大領域。旗下融創文旅並對旗下運營中的文旅城商業項目所有店鋪免除1月25日至2月29日期間全部租金,共計36天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.